Aoxin Q&M's acquisition will raise its exposure to PCR testing demand: Deputy CEO
Add BT as a preferred source
AOXIN Q&M Dental Group is boosting its exposure in the Covid-19 testing space. The Catalist-listed company expects its acquisition of a stake in medical technology company Acumen Diagnostics to improve its top and bottom lines.
The deal is a "very good opportunity" for the company to expand its reach into the medtech business, which has been on a tear since the start of the Covid-19 pandemic, Aoxin Q&M's deputy chief executive Ryan San told The Business Times on Tuesday.
Shareholders can expect stronger financials as soon as the second half of 2021 ending December, and higher dividend payouts, he added.
TRENDING NOW
Nearly half of Apac’s wealthy expect market crash or correction, plan to rotate to cash: study
Yeo’s, Tiger Beer and now Gardenia – flight of food manufacturing from Singapore might be just as planned
AGT raises Nam Cheong stake; Silchester increases holdings of ComfortDelGro
Johor property old hand KSL readies family handover amid market boom
